Contents
Drug Interaction Checker Market 2023 Growth Opportunities and Forecasts
Drugs Interaction Checker Market 2023 Growth Opportunities and Forecasts is a research report that provides a clear view of the global market. The report evaluates the impact of various factors influencing the market and helps identify emerging opportunities.
Interaction control solutions differ in the number of interaction types covered, the source of information, and the size of the knowledge base. Some are available as integration-ready APIs for use in EHR and point-of-care systems.
Market size
The report profiles the key market players and provides an in-depth analysis of their position in the market, business techniques, product portfolio, overall monetary performance and recent trends. It also assesses their growth potential and makes predictions for the coming years.
Many hospitals and telemedicine systems are making drug interaction monitoring available to their patients through apps and websites. Some are integrated with e-prescribing or computerized physician order entry (CPOE) systems. Others provide a modern interface that can be added to existing systems using APIs.
Some DDI screening programs can only detect certain types of interactions, such as those between drugs that treat the same disease. For example, beta blockers and bronchodilators may interact to make asthma worse. Other DDIs are more complex, such as drug-herb or drug interactions, which can decrease a drug’s effectiveness or increase side effects. In a study by Barron’s, 9 DDI software programs were evaluated for their ability to identify these interactions. iFacts and Micromedex were the best, with scores of 390 out of 400.
The global Drug Interaction Checker market is dominated by two major companies, Medscape and WebMD. They each occupy almost a third of the market. The remaining share is split between a number of small and mid-market vendors, including RxList, Liverpool, DynaMed, CVS Caremark and MIMS Australia.
These vendors offer a variety of drug interaction monitoring solutions, including APIs that integrate directly into an EHR system, clinical decision support (CDSS), e-prescription, or automated physician order entry (CPOE) systems. They vary in the number of interaction types covered, the sources of drug information used and the size of their databases.
Adding drug monitoring to an existing system is the fastest way to improve patient safety. However, most DDI screening programs are deficient in recognizing overlapping prescriptions and prescription errors. In addition, they often fail to detect DDIs related to drugs with similar names or pharmacological actions. In a recent study, Barron’s evaluated 9 DDI software programs and found that only iFacts and Micromedex correctly detected overlapping prescriptions.
Market trends
A drug-drug interaction check can help a doctor avoid serious or harmful PDDIs. Nevertheless, they can also produce too many warnings. A study has shown that doctors and pharmacists can become desensitized to the alarms of these systems. As a result, they may overwrite or miss an important warning.
The database contains information on a variety of interactions, including metabolic enzymes and drug transporters (proteins that move drugs in and out of cells). It can also identify the presence of certain substances in a patient’s body, such as herbs, vitamins, or foods.
The database is regularly updated. For example, the latest version of Lexicomp has over 170,000 entries related to in vitro and in vivo data. The database can also provide warnings about pharmacodynamic and pharmacokinetic drug interactions. This is especially useful when treating a group of patients with the same medical condition. The new version also includes a search for interactions with supplements and herbal remedies.
Market Forecasts
For example, a drug-drug interaction checker alerts healthcare providers to inconsistencies between two medications prescribed for a patient. It also scans for interactions between a drug and over-the-counter drugs, herbs, nutritional supplements, or food. It can also detect drug allergies or food allergies and help healthcare professionals select the safest medication for patients.
The database contains both in vitro and in vivo data on the enzymes that break down drugs, drug transporters and other factors that influence how a drug is absorbed or excreted. The DIDB also contains information about the effects of food, vitamins, tobacco and herbal products.
Levy’s work has been recognized with a national award and two decades of independent funding through licensing revenue from companies, medical centers and universities around the world. His team continues to expand and refine the database and its use in reducing drug reactions. The nonprofit Drug Interaction Solutions team at the UW School of Pharmacy works to save lives by preventing side effects, one of the most common causes of death and injury in hospitals.